Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial
- 418 Downloads
GALLIUM is a global phase III study that demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with obinutuzumab plus chemotherapy (G-chemo) versus rituximab plus chemotherapy (R-chemo) in previously untreated patients with follicular lymphoma (FL). In this single-country subgroup analysis, we explored patterns of efficacy and safety in patients enrolled in the GALLIUM study in Japan (Japanese subgroup). Patients were randomized to open-label induction treatment with G-chemo or R-chemo. Responders received maintenance monotherapy with their randomized antibody for up to 2 years. The primary endpoint was investigator-assessed PFS. Overall, 123 patients with FL were randomized in the Japanese subgroup (G-chemo, n = 65; R-chemo, n = 58). The majority of patients received cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (82.9 vs 33.1% in the global GALLIUM FL population). PFS at 3 years was 89.9% (G-chemo) vs. 74.7% (R-chemo); hazard ratio 0.42; 95% confidence interval 0.15, 1.15; P = 0.08. Higher rates of grade 3–5 adverse events (96.9 vs. 89.7%) and serious adverse events (35.4 vs. 22.4%) were observed with G-chemo vs R-chemo, respectively. Neutropenia was frequent in the Japanese subgroup (92.3% G-chemo; 79.3% R-chemo). Overall, the results in the Japanese subgroup were consistent with those in the global GALLIUM population.
KeywordsObinutuzumab Rituximab Follicular lymphoma Japan
The authors would like to thank the UK and German study groups (UK National Cancer Research Institute, German Low Grade Lymphoma Study Group and the East German Study Group Hematology and Oncology) for their scientific support of the GALLIUM study, all of the GALLIUM study investigators, their teams, and the patients for their participation. The GALLIUM trial was sponsored by F. Hoffmann-La Roche Ltd. Medical writing support for this article was provided by Lynda McEvoy, PhD (Gardiner-Caldwell Communications, Macclesfield, UK), funded by Chugai Pharmaceutical Co Ltd.
Compliance with ethical standards
Conflict of interest
KO reports personal fees from Chugai Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, Eisai Co Ltd, Pfizer Inc and Takeda Pharmaceutical Co Ltd. KT reports Grants and personal fees from Chugai Pharmaceutical Co Ltd/Roche, Celgene, Eisai, Janssen Pharmaceuticals, Kyowa Hakko Kirin, Mundipharma, Ono Pharmaceutical and Takeda; Grants from Abbvie, GlaxoSmithKine and Servier; and personal fees from HUYA Bioscience and Zenyaku Kogyo. TK reports Grants and personal fees from Chugai Pharmaceutical Co Ltd, Ono, Gilead, MSD and Zenyaku; Grants from Takeda and Solaisia; and personal fees from Bristol, Kyowa Kirin, Eisai and Janssen. TI, KKumagai, SI, YK, IC, TC, YK, KKubo, KM and NT report no conflicts of interest. KH reports Grants from Chugai Pharmaceutical Co. KO reports Grants and personal fees from Chugai Pharmaceutical Co Ltd and Takara-Bio Inc; and personal fees from Kyowa Hakko Kirin Co Ltd, Ono Pharmaceutical Co Ltd, Bristol-Meyers Squibb, Chugai Pharmaceutical Co Ltd and Alexion Pharmaceuticals Inc. KT reports Grants from Chugai Pharmaceutical Co Ltd, Celgene, Takeda and Mundipharma; consultancy from Huya and Ono Pharma, and lecture fees from Zenyaku Kogyo, Celgene, Huya, Kyowa Hakko Kirin and Chugai Pharmaceutical Co Ltd. MT reports Grants and personal fees from Chugai/Roche, Celgene, BMS, and Janssen Pharmaceuticals; Grants from Kyowa Hakko Kirin; and personal fees from Mundipharma. TU reports personal fees from Janssen Pharmaceuticals, Mundipharma, Celgene, Teijin, Novartis, Nippon Shinyaku, Pfizer, Briston-Myers Squibb, and Meiji Seika Pharama. KI reports Grants from Kenyaku Kogyo, Mundhi, Abbvie, Solasia, Celltrion, Symbio, Astellas, Astellas Amgen, Novartis and Sanofi; Grants and personal fees from Takeda, Eisai, Chugai Pharmaceutical Co Ltd, Gilead, Janssen, Ono, Celgene, MSD, Bayer and Daiichi-Sankyo, personal fees from Kyowa Hakko Kirin; and discloses a relationship with HUYA Bioscience International. IY reports research funding and honoraria from Kyowa Hakko Kirin; research funding from Chugai; and honoraria from Celgene. FI reports Grants and personal fees from Chugai Pharmaceutical Co Ltd, Kyowa Hakko Kirin, and Takeda; Grants from Bristol-Myers-Squibb; and personal fees from Celgene. NU reports research Grants from AMED, Pfizer Co, Sysmex Co, Kyowa Hakko Kirin Co, Bristol-Myers-Squibb, Novartis, Nippon Shinyaku, Fujimoto and Celgene; payment for data monitoring committee membership from CIMIC Co, Takeda Bio Development Center, Lilly Japan, Pfizer Co, Nippon Boehringer-Ingelheim Co, Janssen Pharmaceutical Co, Zenyaku Kogyo Co, Kyowa Hakko Kirin Co, Otsuka Pharm Co, Celgene Co, SymBio Pharmaceutical Co, Huya Bioscience International, and Astellas Pharmaceutical Co; and payment for speaker’s bureau for Chugai Pharmaceutical Co Ltd and Bristol-Myers-Squibb. SI reports Grants from Chugai Pharmaceutical Co Ltd, Kyowa Hakko Kirin, Astellas, Toyama Chemicals, Teijin Pharma, Sanofi, Bayer, J-Pharma, Eli Lilly, and Daiichi Sankyo; and Grants and personal fees from Ono, Janssen, Celgene, Bristol-Myers-Squibb, Novartis, and Takeda. TM reports personal fees from Bristol-Myers-Squibb, Celgene, Esai, Janssen Pharmaceutical, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, Ono Pharmaceuticals, Otsuka Pharmaceuticals, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, and Taiho Pharmaceutical. EU and HK are employees of Chugai Pharmaceutical Co Ltd. HK reports stock ownership for Chugai Pharmaceutical Co Ltd. KA reports subsidies or donations from Meiji Seika Pharma Co Ltd, Takeda Pharmaceutical Co Ltd, Eizai Co Ltd, Kyowa Kirin and the Japan Blood Products Organization.
- 1.Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.CrossRefPubMedGoogle Scholar
- 3.Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986–92.CrossRefPubMedGoogle Scholar
- 5.Rituxan injection prescribing information. 2017. http://www.info.pmda.go.jp/downfiles/ph/PDF/380101_4291407A1027_2_23.pdf. Accessed June 2018.
- 7.NCCN guidelines for treatment of cancer by site. B-cell lymphomas. 2017. http://www.nccn.org/. Accessed June 2018.
- 9.Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–402.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081–93.CrossRefPubMedGoogle Scholar
- 15.Zelenetz AD, Mobasher M, Costa LJ, Flinn I, Flowers CR, Kamnski MS, et al. Safety and efficacy of obinutuzumab (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 GATHER study. Blood. 2013;122:1820.Google Scholar
- 17.Hirayama Y, Ishitani K, Ohta S, Kurosawa M, Kondo T, Takimoto R, Kato J. Long-term survey of 443 cases of advanced-stage follicular lymphoma in Japan during the rituximab era. J Clin Oncol. 2014;32(Suppl):e19504.Google Scholar
- 18.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press; 2008.Google Scholar
- 19.Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–18.Google Scholar
- 23.Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15:1110–7.CrossRefPubMedGoogle Scholar
- 28.Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt RH, et al. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood. 2016;128:613.CrossRefGoogle Scholar
- 29.Esai Co Ltd. Anticancer agent Treakisym® approved in Japan for additional indication as first-line treatment for low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma. 2016. http://www.eisai.com/news/news201689.html. Accessed June 2018.